Summer 2027
MBA Finance Associate
Posted on 7/24/2026
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
No salary listed
New York, NY, USA
Hybrid
Four days on-site per week at Pfizer New York Headquarters in Hudson Yards, Manhattan.
 Finance & Banking (1) |
|---|
Get referred to Pfizer
Find people who can refer or advise you
- Bachelor’s degree
- Enrolled in a Full-Time MBA program
- 1st year MBA student graduating in Spring 2028
- At least 2 years of full-time work experience
- Strong financial skills as well as a proven record in analytics, leadership and communication
- Must be immediately authorized to work in the U.S. on a permanent or indefinitely renewable basis without employer’s sponsorship
- U.S. work visa sponsorship (such as TN, O-1, H-1B, etc.) is not available for this role now or in the future
- Budgeting and forecasting
- Evaluation of outsourcing possibilities
- Pricing issues and drivers
- Risk management
- Capital structure
- Cash flow management
- Co-promotion profits split models
- Investment model development
- Analysis of LoE (loss of exclusivity) impact
- Consulting experience
- Pharmaceutical experience
- Healthcare experience
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Get referred to Pfizer
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Obesity asset MET097i targets 2028 launch to offset $17B–$18B patent cliff losses.
- Oncology revenues grew 7% to $3.8B in Q1 2026, driven by Padcev and Lorbrena.
- FDA approval for Padcev-Keytruda expands bladder cancer treatment to earlier disease stages.
What critics are saying
- Eliquis, Ibrance, Xtandi, and Prevnar 13 lose exclusivity by 2028, dropping $17B revenue.
- Sigvotatug vedotin failed Phase 3 for lung cancer, weakening Seagen's oncology pipeline de-risking.
- Cash flow fell $700M short of covering dividends in 2025, pressuring the 7% yield.
What makes Pfizer unique
- Pfizer leads with four marketed antibody-drug conjugates from its $43B Seagen acquisition.
- The company offers a monthly GLP-1 obesity drug, berobenatide, from Metsera.
- Patent-protected Padcev-Keytruda regimen is the first platinum-free option for bladder cancer.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -4%ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich
Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.
Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.
Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.
Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.